View from Brussels

Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.

Articles

Slovenia brings EU health officials together for increased emphasis on repurposing.

Rhetoric and Realism Colliding on EU Discussions of Drug Repurposing

Promises of "more equitable access for those with severe diseases," "decision-making flexibility where it counts," and more in a bid to win post-Brexit business.

NICE Consults On Its New Assessment Scheme Amid A Blizzard Of Spin

European Commission proposes new bio-defense preparedness plan.

HERA, A Matriach's Device to Save Europeans from the Next COVID

Obligatory Summertime Reading–How to Use the EU's New Clinical Trials Regulation

A draft report from parliament's cancer committee highlights the benefits that precision and personalized medicine offer.

Faint Ripples of Support Detected in Europe for High-Tech Drug Development

Not just COVID is changing the landscape of pharmaceutical policy in Europe.

Convergent Drivers of European Medicines Policy

Allegedly more than 4,000 clinical trials of medicines are missing results on the European trial registry, in violation of transparency rules. 

Putting the Squeeze on Trial Reporting Failings in Europe

A new report from the EMA and EUnetHTA shows a shift towards a more efficient form of collaboration.

Closer European Collaboration on the Ground on HTA and Marketing Authorization—But Under a Political Cloud

Conclusions from the Global Health Summit provide plenty of support for research, innovation, investment, and incentivization.

Is COVID A Game-Changer for Wider Drug Development Policy?

A major international collaboration within ICH features big hitters from across the world's major regulatory authorities and drug firms